Phase 2a Study of IW-9179 to Treat Functional Dyspepsia
This study is currently recruiting participants.
Verified December 2012 by Ironwood Pharmaceuticals, Inc.
Sponsor:
Ironwood Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ironwood Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01712412
First received: October 11, 2012
Last updated: December 5, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objectives of this study are to determine the safety and efficacy of IW-9179 administered to patients with functional dyspepsia (FD).
| Condition | Intervention | Phase |
|---|---|---|
|
Dyspepsia Functional Gastrointestinal Disorders |
Drug: IW-9179 Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Ironwood Pharmaceuticals, Inc.:
Primary Outcome Measures:
- Rate of treatment-emergent adverse events [ Time Frame: Reported at any time after the first dose, including the 14 days of treatment and 7 days of follow up ] [ Designated as safety issue: Yes ]
- Change from baseline 12-lead electrocardiogram (ECG) at day 14 of treatment [ Time Frame: Baseline values taken just prior to first dose (day 1) compared with values taken on the last day of treatment (day 14) ] [ Designated as safety issue: Yes ]
- Change from baseline clinical laboratory evaluations at the last day of treatment (day 14) [ Time Frame: Baseline values taken just prior to first dose (day 1) compared with values taken on the last day of treatment (day 14) ] [ Designated as safety issue: Yes ]
- Change from baseline vital signs at the day 14 visit and at the end of the study (7 days after the last dose) [ Time Frame: Baseline values taken prior to first dose (day 1) compared with values taken at the day 14 visit (14 days after first dose) and at the end of the study (21 days after the first dose) ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Post-meal Symptom Severity (PMSS) Assessment [ Time Frame: Completed at day 1 and day 14 of the Treatment Period ] [ Designated as safety issue: No ]Assessments completed at 15 min prior to dose, just prior to dose, and every 15 minutes after the first dose through 240 minutes (4 hours after first dose)
- Daily Patient Symptom Severity (PSS) Assessment [ Time Frame: Average of daily assessments for the 2 weeks just prior to the first dose compared to: 1) the average of the 2 week treatment period, 2) the average of the first week of treatment and 3) the average of the second week of treatment ] [ Designated as safety issue: No ]Assessments recorded on a daily basis
- Weekly Symptom Relief (SR) Assessments [ Time Frame: Average of week 1 and week 2 prior to treatment compared with the week 1 and week 2 during treatment ] [ Designated as safety issue: No ]Assessments recorded on a weekly basis weekly
- Nepean Dyspepsia Index [ Time Frame: Baseline NDI score (collected just prior to first dose) compared with End of Treatment NDI (collected just prior to last dose) ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 80 |
| Study Start Date: | October 2012 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: IW-9179
Oral IW-9179 taken daily for two weeks
|
Drug: IW-9179 |
|
Placebo Comparator: Placebo
Oral placebo taken daily for two weeks
|
Drug: Placebo |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient meets ROME III criteria for functional dyspepsia (FD)
- Patient has a normal esophagogastroduodenoscopy (EGD) either during the Screening Period or within 2 years of the Screening Visit
Patients who EITHER:
- Have not used a proton pump inhibitor (PPI) within 4 weeks of the Screening Visit, OR
- Have used a PPI at a stable dose for at least 4 weeks prior to the Screening Visit;
- Patient meets symptom severity criteria in the Pretreatment Period
- Patient is fluent and literate in Dutch, French, or English
Exclusion Criteria:
- Patient meets criteria for gastroesophogael reflux disease (GERD, stable regimen of PPIs acceptable), constipation, diarrhea, lower abdominal pain, or gastroparesis
- Patient has a history of inflammatory bowel disease, chronic pancreatitis, small intestinal bacterial overgrowth, celiac disease, lactose intolerance, polycystic kidney disease, interstitial cystitis, or scleroderma
- Any significant neurological disease or a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable; complete remission of other cancers for 5 years or longer is also acceptable)
- History of active alcoholism or drug addiction within 12 months prior to the Screening Visit
- Hospitalized for a psychiatric condition or has made a suicide attempt during the two years before the Screening Visit
- Any organic or structural disease that can cause abdominal pain or discomfort
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01712412
Locations
| Belgium | |
| AZ Sint-Lucas Brugge | Recruiting |
| Brugge, Belgium, 8310 | |
| Contact: Research Coordinator 3250365155 | |
| Antwerp University Hospital | Recruiting |
| Edegem, Belgium, 2650 | |
| Contact: Research Coordinator 3238213323 | |
| Z.O.L. - Campus St. Jan | Recruiting |
| Genk, Belgium, 3600 | |
| Contact: Research Coordinator 3289325151 | |
| Universitair Ziekenhuis Gent | Recruiting |
| Gent, Belgium, 9000 | |
| Contact: Research Coordinator 3293322111 | |
| UZ Leuven | Recruiting |
| Leuven, Belgium, 3000 | |
| Contact: Research Coordinator 3216344225 | |
| CHU Ambroise Pare | Recruiting |
| Mons, Belgium, 7000 | |
| Contact: Research Coordinator 3265392632 | |
| H. Hartziekenhuis Roselare-Menen vzw | Recruiting |
| Roselare, Belgium, 8800 | |
| Contact: Research Coordinator 325137275 | |
| Netherlands | |
| FlevoResearch | Recruiting |
| Almere, Netherlands, 1311 RL | |
| Contact: Research Coordinator 310365497186 | |
| PreCare Trial and Recruitment | Recruiting |
| Beek, Netherlands, 6191 JW | |
| Contact: Research Coordinator 31464758687 | |
| Andromed Breda | Recruiting |
| Breda, Netherlands, 4811 SW | |
| Contact: Research Coordinator 31765310370 | |
| Andromed Eindhoven | Recruiting |
| Eindhoven, Netherlands, 5616GB | |
| Contact: Research Coordinator 31402519267 | |
| Andromed Noord | Recruiting |
| Groningen, Netherlands, 9711 SG | |
| Contact: Research Coordinator 31503187871 | |
| Andromed Leiden | Recruiting |
| Leiden, Netherlands, 2352 RA | |
| Contact: Research Coordinator 31715145543 | |
| Maastricht University Med Ctr | Recruiting |
| Maastricht, Netherlands, 6229 HX | |
| Contact: Research Coordinator 31433876543 | |
| Andromed Rotterdam | Recruiting |
| Rotterdam, Netherlands, 3021 HC | |
| Contact: Research Coordinator 31104254852 | |
Sponsors and Collaborators
Ironwood Pharmaceuticals, Inc.
More Information
No publications provided
| Responsible Party: | Ironwood Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT01712412 History of Changes |
| Other Study ID Numbers: | ICP-112-201 |
| Study First Received: | October 11, 2012 |
| Last Updated: | December 5, 2012 |
| Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products Netherlands: Medicines Evaluation Board (MEB) |
Additional relevant MeSH terms:
|
Dyspepsia Digestive System Diseases Gastrointestinal Diseases Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on May 21, 2013